ProKidney Corp - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of ProKidney Corp Company

ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient’s own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant’s own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).

ProKidney Corp Info



Ticker SymbolPROK

Company nameProKidney Corp

IPO dateJun 30, 2021

CEODr. Bruce Culleton, M.D.

Number of employees204

Security typeOrdinary Share

Fiscal year-endJun 30

Address2000 Frontis Plaza Blvd.

CityWINSTON-SALEM

Stock exchangeNASDAQ Capital Market Consolidated

CountryUnited States of America

Postal code27103

Phone13369997028

Websitehttps://prokidney.com/

Ticker SymbolPROK

IPO dateJun 30, 2021

CEODr. Bruce Culleton, M.D.

Company Executives of ProKidney Corp



Name

Name/Position

Position

Shareholding

Change

Dr. Bruce Culleton, M.D.

Chief Executive Officer, Director

1.54M

--

Mr. Ethan Holdaway

Investor Relations

--

Mr. William F. (Bill) Doyle

Independent Director

--

Mr. Pablo Legorreta

Chairman of the Board

--

Dr. Uma Sinha, Ph.D.

Independent Director

--

Mr. James Coulston, CPA

Chief Financial Officer

--

Ms. Jennifer Fox

Independent Director

--

Dr. Alan M. Lotvin, M.D.

Independent Director

--

Dr. Darin J. Weber, Ph.D.

Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial

--

Dr. Brian J. G. Pereira, M.D.

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Dr. Bruce Culleton, M.D.

Chief Executive Officer, Director

1.54M

--

Mr. Ethan Holdaway

Investor Relations

--

Mr. William F. (Bill) Doyle

Independent Director

--

Mr. Pablo Legorreta

Chairman of the Board

--

Dr. Uma Sinha, Ph.D.

Independent Director

--

Mr. James Coulston, CPA

Chief Financial Officer

--

Revenue Breakdown

No Data

No Data

By Business

By Region

No Data

Shareholding Stats

Updated: Sat, Nov 8

Shareholders

Shareholder Types

Shareholders

Proportion

Tolerantia LLC

16.75%

Suvretta Capital Management, LLC

9.14%

Control Empresarial de Capitales, S.A. de C.V.

7.94%

Morgan Stanley Investment Management Inc. (US)

4.23%

BlackRock Mexico Operadora SA de CV SOFI

2.54%

Other

59.39%

Shareholders

Proportion

Tolerantia LLC

16.75%

Suvretta Capital Management, LLC

9.14%

Control Empresarial de Capitales, S.A. de C.V.

7.94%

Morgan Stanley Investment Management Inc. (US)

4.23%

BlackRock Mexico Operadora SA de CV SOFI

2.54%

Other

59.39%

Shareholder Types

Shareholders

Proportion

Corporation

24.70%

Hedge Fund

10.27%

Investment Advisor

10.23%

Investment Advisor/Hedge Fund

5.98%

Research Firm

2.84%

Individual Investor

1.92%

Endowment Fund

0.74%

Family Office

0.04%

Bank and Trust

0.04%

Other

43.25%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

180

38.60M

28.59%

-15.99M

2025Q2

187

92.52M

71.43%

-12.19M

2025Q1

188

90.99M

70.46%

-13.35M

2024Q4

184

92.39M

74.12%

+21.48M

2024Q3

176

90.75M

73.53%

+26.28M

2024Q2

216

81.85M

70.67%

+19.77M

2024Q1

231

37.73M

58.52%

-31.32M

2023Q4

239

39.92M

63.74%

-31.95M

2023Q3

236

64.28M

104.12%

-21.16M

2023Q2

223

59.02M

95.83%

-21.49M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Tolerantia LLC

22.62M

16.75%

--

Jun 03, 2025

Suvretta Capital Management, LLC

12.34M

9.14%

--

Jun 30, 2025

Control Empresarial de Capitales, S.A. de C.V.

10.72M

7.94%

+2.28M

+27.04%

Apr 22, 2025

Morgan Stanley Investment Management Inc. (US)

5.71M

4.23%

-4.33M

-43.14%

Jun 30, 2025

BlackRock Mexico Operadora SA de CV SOFI

3.43M

2.54%

--

Aug 31, 2025

Operadora de Fondos GBM S.A.B. de C.V.

2.45M

1.81%

--

Aug 31, 2025

Bleichroeder LP

2.00M

1.48%

--

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

1.72M

1.27%

-4.60M

-72.83%

Jun 30, 2025

The Vanguard Group, Inc.

1.57M

1.16%

-3.64M

-69.92%

Jun 30, 2025

Culleton (Bruce)

1.54M

1.14%

+1.54M

--

Mar 17, 2025

Related ETFs



Updated: Thu, Nov 6

Name

Proportion

Schwab U.S. Small-Cap ETF

0.01%

ALPS Medical Breakthroughs ETF

0%

Global X Russell 2000 Covered Call ETF

0%

Schwab U.S. Broad Market ETF

0%

ProShares UltraPro Russell2000

0%

ProShares Hedge Replication ETF

0%

iShares Russell 2000 ETF

0%

Avantis US Equity ETF

0%

Global X Russell 2000 ETF

0%

iShares Russell 2000 Growth ETF

0%

Schwab U.S. Small-Cap ETF

Proportion0.01%

ALPS Medical Breakthroughs ETF

Proportion0%

Global X Russell 2000 Covered Call ETF

Proportion0%

Schwab U.S. Broad Market ETF

Proportion0%

ProShares UltraPro Russell2000

Proportion0%

ProShares Hedge Replication ETF

Proportion0%

iShares Russell 2000 ETF

Proportion0%

Avantis US Equity ETF

Proportion0%

Global X Russell 2000 ETF

Proportion0%

iShares Russell 2000 Growth ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data